Market Overview

Response Biomedical Corp. to Present at Upcoming Investor Conference

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 2, 2013) - Response Biomedical Corp. (TSX:RBM)(OTCBB:RPBIF) today announced that Chief Executive Officer, Jeffrey L. Purvin will be presenting at the OneMedForum Healthcare conference to be held at the Sir Francis Drake Hotel in San Francisco on Wednesday, January 9, 2013 at 10:00 a.m. PT. A link to the webcast will be made available on the day of the presentation and for 60 days thereafter at www.responsebio.com.

About Response Biomedical Corp.

Response develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) platform for clinical and environmental applications. RAMP(R) represents a unique paradigm in diagnostics that provides reliable laboratory quality results in minutes. It is ideally suited to both point of care testing and laboratory use.

The RAMP(R) system consists of a reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack, congestive heart failure, Influenza A+B and RSV through our commercial partners and distributors. In the non-clinical market, RAMP(R) tests are currently provided for the environmental detection of West Nile Virus and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Forward-Looking Statements

Certain statements contained in this news release constitute forward-looking information or forward-looking statements (collectively, "forward-looking statements") with the meaning of applicable securities legislation. Forward-looking statements are made based on assumptions made by the Company regarding various matters. Although the Company believes the expectations reflected in such forward-looking statements, and the assumptions upon which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct.

Readers are cautioned not to place undue reliance on forward-looking statements included in this news release, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.

Many factors may cause the Company's actual results to differ materially from any forward-looking statement, including the factors detailed in the Company's filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our amended annual report on Form 10-K, our quarterly reports on Form 10-Q, our Annual Information Form and other filings with the Securities and Exchange Commission and Canadian securities regulatory authorities.

FOR FURTHER INFORMATION PLEASE CONTACT:
Response Biomedical Corp.
Patricia Massitti
VP, Administration & Corporate Communications
604-456-6010
ir@responsebio.com
www.responsebio.com

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters